主页 > 医学新闻 >
【medical-news】脂肪肝增加丙肝相关肝硬化患者的
By David Douglas
NEW YORK (Reuters Health) Jul 11 - Hepatic steatosis is associated with an increased frequency of hepatocellular carcinoma (HCC) in patients with hepatitis C-related cirrhosis, according to Massachusetts-based researchers.
"Our findings, which associated higher degrees of hepatic steatosis with HCC in patients undergoing liver transplantation for hepatitis C, implicate fatty liver as an accelerant of the development of HCC observed in these patients," senior investigator Dr. Raymond T. Chung told Reuters Health.
Dr. Chung and colleagues at General Hospital, Boston came to this conclusion after a retrospective review involving 94 patients with hepatitis C cirrhosis who underwent transplantation between 1992 and 2005.
According to their report in the June 15th issue of Cancer, 32 patients had evidence of hepatocellular cancer. In the HCC group, 69% had evidence of steatosis compared to 50% of those without HCC.
Compared with no steatosis, the odds ratio for the development of HCC ranged from 1.61 for grade 1 steatosis to 8.02 for grade 3 or 4.
The researchers conclude that steatosis is independently associated with hepatocellular cancer in these patients and may be a useful marker for identifying those at high risk.
Moreover, added Dr. Chung, the findings "suggest that measures to ameliorate fatty liver may be helpful in reducing this risk."
Cancer 2007;109:2490-2496.
http://www.medscape.com/viewarticle/559629 Fatty Liver Tied to Cancer in Hepatitis C Cirrhosis
脂肪肝增加丙肝相关肝硬化患者的肝癌发病率
By David Douglas
NEW YORK (Reuters Health) Jul 11 - Hepatic steatosis is associated with an increased frequency of hepatocellular carcinoma (HCC) in patients with hepatitis C-related cirrhosis, according to Massachusetts-based researchers.
纽约（路透社健康版）7月11日──据麻萨诸塞州研究人员报道，肝脏脂肪变性与丙肝相关肝硬化患者肝细胞癌（HCC）发病率较高有关。
"Our findings, which associated higher degrees of hepatic steatosis with HCC in patients undergoing liver transplantation for hepatitis C, implicate fatty liver as an accelerant of the development of HCC observed in these patients," senior investigator Dr. Raymond T. Chung told Reuters Health.
资深研究人员Raymond T. Chung博士告诉路透社说，“我们在对丙肝肝移植患者的研究中发现，HCC常伴有较严重的肝脏脂肪变性。该结果表明，脂肪肝是这些患者发生HCC的一个催化剂。”
Dr. Chung and colleagues at General Hospital, Boston came to this conclusion after a retrospective review involving 94 patients with hepatitis C cirrhosis who underwent transplantation between 1992 and 2005.
Chung 博士和波士顿总医院的同事在回顾性研究1992年~2005年期间行肝移植术的94名丙肝肝硬化患者后得出上述结论。
According to their report in the June 15th issue of Cancer, 32 patients had evidence of hepatocellular cancer. In the HCC group, 69% had evidence of steatosis compared to 50% of those without HCC.
他们在《Cancer》6月15日刊报道，32名患者被诊断为肝细胞癌，肝脏脂肪变性在HCC患者中占69%，而在无HCC患者中占50%。
Compared with no steatosis, the odds ratio for the development of HCC ranged from 1.61 for grade 1 steatosis to 8.02 for grade 3 or 4.
与无脂肪变性的患者相比，1级脂肪变患者发生HCC的比值比为1.61，3~4级脂肪变患者发生HCC的比值比为8.02。
The researchers conclude that steatosis is independently associated with hepatocellular cancer in these patients and may be a useful marker for identifying those at high risk.
研究人员总结说，在丙肝肝硬化患者中脂肪变性与肝细胞癌独立相关，这可能成为识别肝细胞癌高危人群的一个有用标志物。
Moreover, added Dr. Chung, the findings "suggest that measures to ameliorate fatty liver may be helpful in reducing this risk."
然而，Chung博士补充说，该结果“表明改善脂肪肝的措施很可能有助于降低这些患者肝细胞癌的发病风险。”
Cancer 2007;109:2490-2496.
编译：
脂肪肝增加丙肝相关肝硬化患者的肝癌发病率
纽约（路透社健康版）7月11日──据麻萨诸塞州研究人员报道，肝脏脂肪变性与丙肝相关肝硬化患者肝细胞癌（HCC）发病率较高有关，脂肪肝是这些患者发生HCC的一个催化剂。研究结果发表在《Cancer》杂志6月15日刊（Cancer 2007;109:2490-2496.）。
资深研究人员Raymond T. Chung博士和波士顿总医院的同事通过对1992年~2005年期间行肝移植术的94名丙肝肝硬化患者进行回顾性研究后发现，HCC常伴有较严重的肝脏脂肪变性。研究中共有32名患者被诊断为肝细胞癌，肝脏脂肪变性在HCC患者中占69%，而在无HCC患者中占50%。肝细胞癌的发生风险还与脂肪变性程度相关，与无脂肪变性的患者相比，1级脂肪变患者发生HCC的比值比为1.61，3~4级脂肪变患者发生HCC的比值比为8.02。
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-02-19 05:22
医学,生命科学网